NDA 022290 · Ge Healthcare
Adreview
Iobenguane Sulfate I-123 · Intravenous
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Mar 5, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2008
Sep 19, 2008
Approved uses
2
Original approval plus efficacy supplements
Registered trials
17
7 Phase 3, 1 recruiting
FAERS reports
114
64 serious, 6 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 10, 2024.
AdreView is a radiopharmaceutical agent for gamma-scintigraphy indicated for: use in the detection of primary or metastatic pheochromocytoma or neuroblastoma as an adjunct to other diagnostic tests ( 1.1 ) scintigraphic assessment of sympathetic innervation of the myocardium by measurement of the heart to mediastinum (H/M) ratio of radioactivity uptake in patients with New York Heart Association (NYHA) class II or class III heart failure and left ventricular ejection fraction (LVEF) ≤ 35%. Among these patients, AdreView may be used to help identify patients with lower one and two year mortality risks, as indicated by an H/M ratio ≥ 1.6. ( 1.2 ) Limitations of Use: In patients with congestive heart failure, AdreView utility has not been established for: selecting a therapeutic intervention or for monitoring the response to therapy; using the H/M ratio to identify a patient with a high risk for death. 1.1 Pheochromocytoma and Neuroblastoma AdreView is a radiopharmaceutical indicated for use in the detection of primary or metastatic pheochromocytoma or neuroblastoma as an adjunct to other diagnostic tests. 1.2 Congestive Heart Failure AdreView is indicated for scintigraphic assessment of sympathetic innervation of the myocardium by measurement of the heart to mediastinum (H/M) ratio of radioactivity uptake in patients with New York Heart Association (NYHA) class II or class III heart failure and left ventricular ejection fraction (LVEF) ≤ 35%. Among these patients, AdreView may be used to help identify patients with lower one and two year mortality risks, as indicated by an H/M ratio ≥ 1.6. Limitations of Use: In patients with congestive heart failure, AdreView utility has not been established for: selecting a therapeutic intervention or for monitoring the response to...
Mechanism: Iobenguane is similar in structure to the antihypertensive drug guanethedine and to the neurotransmitter norepinephrine (NE). Iobenguane is, therefore, largely subject to the same uptake and accumulation pathways as NE. Iobenguane is taken up by the NE transporter in adrenergic nerve terminals and stored in the presynaptic storage vesicles. Iobenguane accumulates in adrenergically innervated tissues such as the adrenal medulla, salivary glands, heart, liver, spleen and lungs as well as tumors derived from the neural crest. By labeling iobenguane with the isotope iodine 123, it is possible to...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 20, 2013 Supplement 1 · Efficacy LabelLetter
- Sep 19, 2008 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
- ADREVIEW · IOBENGUANE SULFATE I-123 10mCi/5ML (2mCi/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Iobenguane I-123" as an intervention, any sponsor and status, largest first.
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)Pivotal-lookingRecruiting
Children's Oncology GroupResearch network
NCT03126916 · 750 participants (planned) · Start May 14, 2018 · Primary completion Sep 30, 2030
Drug: Busulfan; Carboplatin and 13 more · For: Ganglioneuroblastoma; Ganglioneuroblastoma, Nodular; Neuroblastoma
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 164 sites in all
- Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular DiseasePivotal-lookingCompleted
GE HealthcareIndustry
NCT00126425 · 587 participants · Start Jul 2005 · Primary completion Jul 2008
Drug: 123I-mIBG (meta-iodobenzylguanidine) · For: Heart Failure, Congestive
Sites: Princeton, New Jersey
- Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular DiseasePivotal-lookingCompleted
GE HealthcareIndustry
NCT00126438 · 515 participants · Start Jul 2005 · Primary completion Jul 2008
Drug: 123I-mIBG (meta-iodobenzylguanidine) · For: Heart Failure, Congestive
Sites: Princeton, New Jersey
- International Study to Determine if AdreView Heart Function Scan Can be Used to Identify Patients With Mild or Moderate Heart Failure (HF) That Benefit From Implanted Medical DevicePivotal-lookingTerminated
GE HealthcareIndustry
NCT02656329 · 395 participants · Start Dec 30, 2015 · Primary completion May 4, 2018
Drug: Iobenguane I -123 Injection; Thyroid blocking and 1 more · For: Heart Failure
Sites: Birmingham, Alabama; Bakersfield, California; La Mesa, California · 94 sites in all
- Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or NeuroblastomaPivotal-lookingCompleted
GE HealthcareIndustry
NCT00126412 · 251 participants · Start Aug 2, 2005 · Primary completion Sep 27, 2006
Drug: 123I-mIBG (meta-iodobenzylguanidine) · For: Pheochromocytoma; Neuroblastoma
Sites: Princeton, New Jersey
GE HealthcareIndustry
NCT01936649 · 63 participants · Start Aug 2013 · Primary completion Feb 2014
Drug: AdreView (Iobenguane I 123 Injection) · For: Heart Failure (HF); Ventricular Dysfunction, Left
Sites: Princeton, New Jersey
- MIBG in Aging and Neurologic DisordersEnrolling by invitation
Mayo ClinicAcademic, hospital or other
NCT05514106 · 50 participants (planned) · Start May 8, 2023 · Primary completion Sep 2027
Drug: meta-iodobenzylguanidine (MIBG) (123I) · For: Lewy Body Disease; Dementia; Parkinsonism and 2 more
Sites: Rochester, Minnesota
- Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)Active, not recruiting
Children's Oncology GroupResearch network
NCT04385277 · 41 participants · Start Dec 31, 2020 · Primary completion Jun 30, 2023
Drug: Dinutuximab; Irinotecan and 3 more · For: Ganglioneuroblastoma, Nodular; Neuroblastoma
Sites: Mesa, Arizona; Little Rock, Arkansas; Downey, California · 77 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- no adverse event41
- neutropenia22
- drug ineffective21
- radioisotope scan abnormal20
- mucosal inflammation14
- fatigue5
- febrile neutropenia5
- neuroblastoma recurrent5
- product use issue4
- pyrexia4
- therapy partial responder4
- vomiting4
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2013 | 4 |
| 2014 | 3 |
| 2015 | 6 |
| 2016 | 10 |
| 2017 | 14 |
| 2018 | 3 |
| 2019 | 4 |
| 2020 | 9 |
| 2021 | 5 |
| 2022 | 21 |
| 2023 | 11 |
| 2024 | 12 |
| 2025 | 4 |
| 2026 | 7 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- 123I-mIBG scintigraphy to predict risk for adverse cardiac outcomes in heart failure patients: design of two prospective multicenter international trials.
Jacobson AF, Lombard J, Banerjee G, et al. · J Nucl Cardiol 2009 · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
Sponsor: Ge Healthcare
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.